Buprenorphine in long-term control of chronic pain in cancer patients

摘要: The aim of this randomized open-label prospective study was to evaluate the analgesic activity buprenorphine in a transdermal formulation for cancer chronic pain control versus sustained-release morphine, all cases combined with oral tramadol. A system 35 microg/h applied first group patients (BT); second received 60 mg/day morphine (MT). In both groups tramadol administered maximum 200 mg daily, case need. administration resulted significant differences physical (P = 0.01), mental health 0.03) and vitality 0.001). These data indicated that BT showed an improvement positive effect on quality life.